X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA IPCA LABS NATCO PHARMA/
IPCA LABS
 
P/E (TTM) x 16.7 28.1 59.6% View Chart
P/BV x 18.0 3.3 541.6% View Chart
Dividend Yield % 0.6 0.1 450.2%  

Financials

 NATCO PHARMA   IPCA LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
IPCA LABS
Mar-18
NATCO PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs877695 126.1%   
Low Rs424400 105.9%   
Sales per share (Unadj.) Rs223.4260.2 85.9%  
Earnings per share (Unadj.) Rs31.119.0 163.8%  
Cash flow per share (Unadj.) Rs40.333.1 121.8%  
Dividends per share (Unadj.) Rs5.001.00 500.0%  
Dividend yield (eoy) %0.80.2 421.1%  
Book value per share (Unadj.) Rs219.5213.0 103.0%  
Shares outstanding (eoy) m33.07126.20 26.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.92.1 138.3%   
Avg P/E ratio x20.928.9 72.5%  
P/CF ratio (eoy) x16.116.6 97.4%  
Price / Book Value ratio x3.02.6 115.2%  
Dividend payout %16.15.3 305.3%   
Avg Mkt Cap Rs m21,50469,120 31.1%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,1287,359 15.3%   
Avg. sales/employee Rs ThNM2,477.4-  
Avg. wages/employee Rs ThNM555.2-  
Avg. net profit/employee Rs ThNM180.6-  
INCOME DATA
Net Sales Rs m7,38932,836 22.5%  
Other income Rs m167418 40.0%   
Total revenues Rs m7,55633,254 22.7%   
Gross profit Rs m1,7934,505 39.8%  
Depreciation Rs m3041,777 17.1%   
Interest Rs m366240 152.5%   
Profit before tax Rs m1,2902,905 44.4%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309511 60.4%   
Profit after tax Rs m1,0272,394 42.9%  
Gross profit margin %24.313.7 176.9%  
Effective tax rate %23.917.6 136.1%   
Net profit margin %13.97.3 190.7%  
BALANCE SHEET DATA
Current assets Rs m3,68119,455 18.9%   
Current liabilities Rs m3,12310,076 31.0%   
Net working cap to sales %7.628.6 26.5%  
Current ratio x1.21.9 61.1%  
Inventory Days Days8998 91.4%  
Debtors Days Days5967 87.7%  
Net fixed assets Rs m7,68520,260 37.9%   
Share capital Rs m331252 131.0%   
"Free" reserves Rs m6,67026,633 25.0%   
Net worth Rs m7,25926,886 27.0%   
Long term debt Rs m9552,340 40.8%   
Total assets Rs m11,95741,173 29.0%  
Interest coverage x4.513.1 34.5%   
Debt to equity ratio x0.10.1 151.1%  
Sales to assets ratio x0.60.8 77.5%   
Return on assets %11.76.4 182.2%  
Return on equity %14.28.9 158.9%  
Return on capital %20.710.8 192.6%  
Exports to sales %39.447.6 82.6%   
Imports to sales %5.714.9 38.3%   
Exports (fob) Rs m2,90815,642 18.6%   
Imports (cif) Rs m4214,884 8.6%   
Fx inflow Rs m3,44515,642 22.0%   
Fx outflow Rs m7034,884 14.4%   
Net fx Rs m2,74310,759 25.5%   
CASH FLOW
From Operations Rs m1,4403,411 42.2%  
From Investments Rs m-1,089-1,354 80.4%  
From Financial Activity Rs m-353-1,304 27.0%  
Net Cashflow Rs m-1753 -0.2%  

Share Holding

Indian Promoters % 52.0 45.9 113.4%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 11.4 68.8%  
FIIs % 16.6 25.3 65.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.4 149.4%  
Shareholders   25,395 36,892 68.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS